Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 52

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 52
---
 31, 2024, certain information regarding stock vested and stock options exercised during the last fiscal year with respect to the named executive officers.

|                   |     | Option Awards        |        |     |                |           |     | Stock Awards        |        |     |                |         |
| Name              |     | Number of Shares     
 Acquired on Exercise 
 (#)                  |        |     | Value Realized 
 on Exercise    
 ($)(1)         |           |     | Number of Shares    
 Acquired on Vesting 
 (#)                 |        |     | Value Realized 
 on Vesting     
 ($)(2)         |         |
| Christopher Peetz |     |                      | 34,013 |     |                | 1,267,324 |     |                     | 30,000 |     |                | 825,666 |
| Eric Bjerkholt    |     |                      |      — |     |                |         — |     |                     | 18,334 |     |                | 768,378 |
| Peter Radovich    |     |                      |      — |     |                |         — |     |                     |  8,147 |     |                | 223,535 |
| Joanne Quan, M.D. |     |                      |      — |     |                |         — |     |                     |      — |     |                |       — |

(1) The value realized on exercise is calculated as the difference between the closing price of our common stock on the date of exercise and the applicable exercise price of such options, multiplied by the number of shares underlying the options that were exercised.

(2) The value realized on vesting is based on the number of shares of our common stock underlying the RSU awards that vested, multiplied by the closing market price of our common stock on the vesting date.

Potential Payments Upon Termination or Change in Control

The following is a discussion of the severance and change in control-related payments and benefits due to our named executive officers under certain circumstances. Our Board may approve revisions, amendments or additions to these benefits from time to time.

Regardless of the manner in which a named executive officer’s service terminates, the named executive officer is entitled to receive amounts earned during his or her term of service, including salary and unused vacation pay.

We maintain a severance benefit plan and have entered into a severance benefit plan participation agreement with each of our named executive officers. Pursuant to these agreements, upon